Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Vaxcyte Inc. Common Stock — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.73 (market cap $44.60B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 4.2× Vaxcyte Inc. Common Stock's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is more actively traded (3,957,816 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 67 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| JEPQ | PCVX | |
|---|---|---|
Market Cap | $44.60B | $10.51B |
Volume | 3,957,816 | 2,644,694 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $73.82 |
52-Week Low | $53.77 | $40.32 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.92, showing minimal daily movement with a neutral technical signal. The ETF maintains a covered-call strategy focused on Nasdaq exposure, generating monthly income through dividends. Recent distributions have shown variability, with payouts ranging from $0.57 to $0.70 per share. Moving averages indicate bullish momentum while oscillators remain neutral, suggesting balanced near-term positioning.
The ETF offers high-yield income potential with an estimated 11% annualized yield, though price appreciation may be limited by the covered-call strategy. Key risks include market volatility dependence and potential tax implications from return of capital. Institutional interest remains strong, with recent acquisitions signaling confidence in the income strategy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
